REGN, leader in monoclonal antibodies would likely be the buyer. I actually am thinking very much along the same lines as you...ENZC & BioClonetics would give any buyer the Clone 3 patent for the next 15 years and the blueprints to cure HIV/COVID and pretty much any other viral infection using monoclonal anitbodies. As well, gives them the Cotropia IP (worth plenty) and the peace of mind that lawsuits won't come at them later down the road. BIG +.
I honestly see many paths but I do believe that acquisition is in their future. Clone 3 will be needed by the large biotechs as it has significant commercial value, as already proven in court. As well, Clone 3 seems to have the broadest usage against many viral strains at once vs. other monoclonal antibodies. They are a very significant piece to the puzzle. ENZC and BioClonetics is like "having the last piece of the monoclonal puzzle", maybe the most valuable...who knows.
What I do know is this is solid and is being given the right exposure on the global stage. Even a lot of the research scientists are saying that they hope to have monoclonal antibodies as a treatment protocol in the near future.
REAL COMPANY + VALUABLE MONOCLONAL PATENTS + GLOBAL NEED = BIG $$$$$$$$
Then, we look at the near-term catalysts:
1) Getting current
2) Merger
3) Application is awaiting approval for funding for the gov't, specifically the NIH
4) Merger with BioClonetics will give this new entity a competitive edge with a Patent on Clone 3 for the next 15 years boxing out any other Pharma from using Clone 3 <-- very important, creates barrier to entry
HUGE and these are just a few of the positive catalysts approaching very quickly. The BoD exchange, from my experience, is just that...pretty much confirmation that they are going to move forward and accelerate as quick as possible.
IMO, this will be bought, but who knows at what price given the legitimacy of this all. Many, many more green days ahead.
Anyway, just my .02
Cheers,
CPM
